A newly-published prospective randomized controlled trial across 24 hospitals led by State Key Laboratory of Kidney Disease in Chinese PLA General Hospital demonstrated similar efficacy of the domestic (Changfu) and Baxter dialysis solutions, and by an “evaluation- technology optimization- reevaluation” process, the safety of Changfu dialysis solution was improved. Also, a dosage of 6L/d proved enough to provide adequate dialysis within one year. This study is of great importance to Chinese domestic peritoneal dialysis development.
↧